The overall aim of the ADCS is to advance research in the development of interventions that might be useful for treating, delaying, or preventing AD, particularly interventions that might not be developed by industry. In particular, the ADCS "has focused on instrument and trial methodology, and the testing of potential therapeutics that might not otherwise be studied by the pharmaceutical industry. For the coming grant cycle, the ADCS will continue its efforts to advance therapeutics through controlled clinical trials, development o novel instruments and trial designs, recruitment efforts (with particular attention to recruitment f minority subjects). The organization will continue its recent emphasis on collaboration and data sharing.
Specific Aims :
Aim 1 : Test interventions to Improve cognition, slow the rate of decline, or delay/prevent the onset of AD. Three of the four projects in this application aim to slow disease progression.
Aim 2 : Test an intervention to ameliorate behavioral symptoms. We will extend promising early results supporting an adrenergic approach amelioration of behavioral symptoms with a multicenter trial of prazosin.
Aim 3 : Design new instruments for use in clinical trials. For the present cycle, we have incorporated instrument development into our largest project, the A4 trial.
Aim 4 : Develop novel and innovative approaches to AD clinical trial design. The A4 trial utilizes a new trial design to test a leading intervention at the earliest feasible stge of disease, preclinical AD.
Aim 5 : Develop novel and innovative approaches to AD clinical trial analysis. The Biostatistics Core will continue efforts to advance analytical approaches to AD trial design. Work will continue on optimal modeling of longitudinal data, including novel methods to link diverse datasets.
Aim 6 :.Expand the range of individuals studied in AD studies to include at-risk individuals and those with MCI. The ADCS has focused its methodological research on early-stage trials, and for this cycle, the two largest projects target preclinical AD and mild cognitive impairment.
Aim 7 : Enhance the recruitment of minority groups into AD studies. For the coming cycle, the ADCS Minority Recruitment Core will expand outreach efforts, and we will require sites to meet minority enrollment targets in our two largest trials.
There is no greater health care need than the development of effective therapy for AD. With aging baby boomers now at the age of risk for AD, the epidemic will accelerate. The ADCS, since its initial funding over 20 years ago, has accrued more experience in AD trials than any other public or private, organization. It is committed to optimall sharing its experience and resources as widely as feasible.
|Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Amyloid and APOE ?4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82:1760-7|
|Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71:1379-85|
|Rafii, Michael S; Taylor, Curtis S; Kim, Hyun T et al. (2014) Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 29:159-65|
|Whitehouse, Peter J (2014) The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 88:677-81|
|Burstein, Aaron H; Grimes, Imogene; Galasko, Douglas R et al. (2014) Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 14:12|
|Donohue, Michael C; Jacqmin-Gadda, Hélène; Le Goff, Mélanie et al. (2014) Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10:S400-10|
|Samieri, Cécilia; Proust-Lima, Cécile; M Glymour, Maria et al. (2014) Subjective cognitive concerns, episodic memory, and the APOE ?4 allele. Alzheimers Dement 10:752-759.e1|
|Galasko, Douglas; Bell, Joanne; Mancuso, Jessica Y et al. (2014) Clinical trial of an inhibitor of RAGE-A? interactions in Alzheimer disease. Neurology 82:1536-42|
|Sperling, Reisa A; Rentz, Dorene M; Johnson, Keith A et al. (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13|
|Papay, Kimberly; Xie, Sharon X; Stern, Matthew et al. (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826-33|
Showing the most recent 10 out of 14 publications